Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
NCT ID: NCT01436214
Last Updated: 2015-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2011-08-31
2017-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
NCT03137758
Study Using CP-461 to Treat Advanced Prostate Cancer
NCT00036075
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01283373
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
NCT03042468
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
NCT01090765
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
APC-100
APC-100
Daily oral, dose escalation, 28-day cycle(s)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
APC-100
Daily oral, dose escalation, 28-day cycle(s)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have progressive disease
* Patients must have had prior treatment with bilateral orchiectomy or androgen deprivation therapy with an LHRH-blocker with evidence of treatment failure
Exclusion Criteria
* Patients with prior chemotherapy given for castrate-resistant prostate cancer
* Patients with prior radiation therapy completed less than 4 weeks prior enrollment
* Patients with prior investigational therapies within 4 weeks before treatment with APC-100
* Evidence of active second malignancy
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Adamis Pharmaceuticals Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elisabeth I Heath, MD
Role: PRINCIPAL_INVESTIGATOR
Wayne State University
Jeremy Cetnar, MD
Role: PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karmanos Cancer Institute
Detroit, Michigan, United States
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APC-100-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.